Quanterix

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Quanterix reports strong Q4 revenue, eyes growth in neurology diagnostics

Quanterix's Q4 performance showcased revenue growth and margin improvement, underpinned by advancements in assay manufacturing and the launch of new tests. The company faces challenges in revenue management and cost control but has opportunities to drive growth through core products and competitive positioning in neurology diagnostics.

Quanterix reports robust Q1 earnings, eyes neuro research growth

Quanterix delivered strong Q1 results with revenue growth and margin improvements, while facing challenges in cash management and meeting revised guidance targets.
The company's focus on neuro research and clinical applications, along with its transformation plan, positions it well for future growth and market leadership.
Analyst inquiries highlighted areas for improvement and clarity, signaling the need for continued strategic communication and operational enhancements.

Quanterix reports robust Q2 earnings, eyes growth in diagnostics market

Quanterix's Q2 performance reflects strong revenue growth and improved profitability.
The company's focus on innovative diagnostics for Alzheimer's and neurological therapies positions it well for future growth.
Despite challenges in leadership transition and addressing specific patient needs, Quanterix remains optimistic about market adoption of blood biomarkers.

Quanterix reports strong Q3 revenue growth and advances in Alzheimer's diagnostics

Quanterix's Q3 performance reflects revenue growth, improved gross margins, and strategic collaborations in blood biomarker testing for Alzheimer's disease.
The company's strengths in expanding platform access, operational efficiency, and multimarker approaches present growth opportunities in diagnostics.
Challenges include meeting revenue growth expectations, maintaining high sensitivity levels in diagnostics, and balancing margin improvements with investments.
Opportunities exist in leveraging partnerships, developing innovative biomarker solutions, and capitalizing on the demand for comprehensive diagnostic tools in healthcare.

Quanterix reports record revenue in Q4 2023, eyes Alzheimer's diagnostics

Quanterix's Q4 2023 performance reflects strong revenue growth, improved margins, and strategic focus on innovation and market expansion.
While challenges in capital allocation and sustaining growth persist, the company's opportunities in menu expansion and Alzheimer's diagnostics are promising.
Overall, Quanterix's financial outlook for 2024 appears positive, with a clear roadmap for growth and continued market penetration.

Quanterix reports revenue growth and innovation drive amidst competition challenges

Quanterix's Q1 2024 performance reflects revenue growth, margin improvement, and innovation in disease detection assays, positioning the company for future success.
Strategic strengths include strong gross margins, successful product launches, and growth in Accelerator Lab services, driving revenue and market presence.
Challenges include competition assessment, margin maintenance, and regulatory milestones, while opportunities exist in innovation, revenue growth, and profitability focus.

Quanterix reports robust Q3 earnings, eyes growth in Alzheimer's diagnostics

Quanterix's strong revenue growth, focus on innovation, and strategic priorities position the company for continued success in the diagnostics market.
While facing challenges in maintaining gross margins and navigating regulatory landscapes, Quanterix has opportunities to drive growth through advanced diagnostics and market expansion.
By balancing customer mix, expanding menu offerings, and investing in new technologies, Quanterix is poised to capitalize on the growing demand for precision medicine and Alzheimer's disease testing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced operating results for the three months ended June 30, 2022. Second Quarter 2022 Financial Highlights Q2 total revenue was $23.5M versus prior year Q2 total revenue of $25.4M, a decrease of 7.4%; Q2 product revenue was $14.8M versus prior year Q2 product revenue of $18.7M, a decrease of 20.8%; Q2 service and other revenue

Quanterix Corporation Releases Operating Results for Second Quarter 2022, Announces Business Re-Alignment Plan and Revises 2022 Guidance

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 1:30 p.m. ET in Boston, MA. Toloue will also host one-on-one and group meetings with institutional investors that day. A live webcast of the conversation will be ava

Quanterix to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Quanterix Corporation (QTRX): Can Its 5.1% Jump Turn into More Strength?

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced it will host a conference call on Monday, August 8, 2022, to discuss its second quarter 2022 financial results. The call will begin at 4:30 PM Eastern Time. It will be hosted by Masoud Toloue, the Company's President and Chief Executive Officer, and Michael Doyle, the Company's Chief Financial Officer. Quanterix will issu

Quanterix' Second Quarter 2022 Earnings Conference Call

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced the validation of a laboratory developed test (LDT) to quantitatively measure phospho-Tau 181 (pTau-181) in plasma as an aid in diagnostic evaluation of Alzheimer's disease (AD). Quanterix' LDT – the first pTau-181 plasma test released for clinical use in the U.S. – is a quantitative immunoassay intended for the measureme

Quanterix Launches First pTau-181 Plasma Laboratory Developed Test for Clinical Diagnostic and Research Applications in the U.S.

Thermo Fisher Scientific

NATICK, Mass.--(BUSINESS WIRE)--Mercy BioAnalytics appoints Dawn Mattoon, PhD, as Chief Operating Officer to strengthen management team behind novel early cancer detection platform.

Mercy BioAnalytics Appoints Dawn Mattoon, PhD, as Chief Operating Officer

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chief Executive Officer, Masoud Toloue, will join the Goldman Sachs 43rd Annual Global Healthcare Conference for a fireside chat on June 16, 2022 at 8:40 a.m., EST. To register for the live webcast, please visit: https://kvgo.com/gs/quanterix-corp-june-2022. Toloue will also host one-on-one meetings

Quanterix to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

Catalent

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Karen A. Flynn, Senior Vice President and Chief Commercial Officer of Catalent Pharma Solutions (NYSE: CTLT), has been appointed to Quanterix' Board of Directors effective June 6, 2022. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management expe

Quanterix Announces Appointment of Karen A. Flynn to Board of Directors

Quanterix Corporation (NASDAQ:QTRX ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Mike Doyle - CFO Masoud Toloue - President & CEO Conference Call Participants Max Masucci - Cowen and Company Kyle Mikson - Canaccord Matt Sykes - Goldman Sachs Puneet Souda - SVB Leerink Operator Good day, and thank you for standing by. Welcome to the Quanterix Corporation Q1 2022 Earnings Conference Call.

Quanterix Corporation (QTRX) CEO Masoud Toloue on Q1 2022 Results - Earnings Call Transcript

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation Releases Operating Results for First Quarter 2022

Quanterix Corporation Releases Operating Results for First Quarter 2022

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation to Release First Quarter 2022 Financial Results on May 10, 2022

Quanterix Corporation to Release First Quarter 2022 Financial Results on May 10, 2022

Quanterix Corporation (QTRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quanterix Corporation (QTRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced its Simoa® technology supported a large international and comprehensive study to establish reference ranges of sNfL to assess disease activity and drug response in MS patients at the individual level, according to a recent study published in The Lancet Neurology. Researchers from the University Hospital Basel

Quanterix' Simoa® Technology Powers Large, International Comprehensive Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Disease Activity in Multiple Sclerosis (MS) Patients

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Receives Funding from the Alzheimer's Drug Discovery Foundation to Accelerate Alzheimer's Disease Diagnostic Plasma Test Development

Quanterix Receives Funding from the Alzheimer's Drug Discovery Foundation to Accelerate Alzheimer's Disease Diagnostic Plasma Test Development

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix to Participate in Barclays Global Healthcare Conference

Quanterix to Participate in Barclays Global Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix to Participate in The Cowen 42nd Annual Health Care Conference On March 9

Quanterix to Participate in The Cowen 42nd Annual Health Care Conference On March 9

Quanterix Corporation (QTRX) CEO Kevin Hrusovsky on Q4 2021 Results - Earnings Call Transcript

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a collaboration with Eli Lilly and Company (Lilly) to advance the diagnosis, monitoring and treatment of Alzheimer's disease. As part of the collaboration, Quanterix will receive a non-exclusive, world-wide license to Lilly's proprietary P-tau217 antibody technology for potential near-term use in research

Quanterix Announces New Agreements with Lilly to Advance Alzheimer's Disease Diagnosis and Treatment

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced its executive leadership succession plan designed to leverage the Company's strong foundation for growth. Effective April 25, 2022, Chairman and Chief Executive Officer Kevin Hrusovsky will become Executive Chairman of the Board and President Masoud Toloue will succeed Hrusovsky as CEO and join Quanterix' Boa

Quanterix Announces Executive Leadership Succession Plan

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced financial results for the fourth quarter and twelve months ending December 31, 2021. “We‘ve reached an important inflection point with the achievement of several key milestones, namely, our license and collaboration agreements with Eli Lilly, FDA Breakthrough Device Designation for plasma pTau-181 for Alzheim

Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2021

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has been recognized by leading workplace culture and corporate brand reputation platform, Comparably, in its 2021 Best Places to Work Awards. Based on more than 1,000 ratings and 40 participants within Quanterix, the company amassed awards in the following five categories: Best Company for Diversity, Best

Quanterix Corporation Garners Five Best Places to Work Awards from Comparably

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation to Release Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

Quanterix Corporation to Release Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix to Participate in the SVB Leerink Global Healthcare Conference

Quanterix to Participate in the SVB Leerink Global Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--UK Dementia Research Institute Biomarker Factory Powers Alzheimer's Disease Breakthroughs with Quanterix Simoa® Technology

UK Dementia Research Institute Biomarker Factory Powers Alzheimer's Disease Breakthroughs with Quanterix Simoa® Technology

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced its Simoa® technology was instrumental in revealing high prevalence of Epstein-Barr virus (EBV) associated with multiple sclerosis (MS), according to a recent study published in the journal Science. Principal Investigator, Dr. Albert Ascherio, epidemiologist at the Harvard T.H. Chan School of Public Health, i

News for Quanterix Stock (QTRX)